explore -WSS

explore

author：knowledge 2025-08-30 14:32:05 - browse：7123

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Hospital price transparency does save money, advocate argues

Wikipedia

knowledge

WSS

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Medical device trials still don't enroll enough women, study finds

First Opinion Podcast: Long Covid needs a new approach

Curing rare childhood diseases will falter unless Congress steps up

Teladoc has a new CEO, but challenges remain the same

How faith leaders like me can help address America's obesity epidemic

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Psychedelics group wrestles with new pharma identity

Why health workers in Gaza are injured or die at high rates

DIEP, the 'gold standard' of breast reconstruction, is under threat

NIH tests clinical research in primary care with $30 million program

Cancer drug shortages should be causing more outrage

Health care court cases: Humana, Sutter, Novant

Affirmative action in medical school literally saved lives

CEOs share strategies for surviving biotech slump

Walensky prepares to leave CDC — and Congress — behind

Medicare reduced heart disease by changing how it pays doctors

focus

FDA gives detailed accounting of AI

Solve the antibiotic resistance crisis with preventive drugs

2023 STAT Wunderkinds: get to know the winners

Lawmakers consider Medicare pay reforms for doctors

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Wikipedia

hotspot

knowledge

hotspot